文献速递瓣膜病与结构性心脏病

经导管三尖瓣修复术1年结局

1-Year Outcomes of Transcatheter Tricuspid Valve Repair.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

1年时三尖瓣反流严重程度显著降低,全因死亡和心衰住院的Kaplan-Meier无事件率分别为87.9%和78.5%,功能状态和生活质量显著改善。

要点

  • PASCAL系统治疗三尖瓣反流1年时86.0%患者反流降至中度或以下。
  • 1年全因死亡和心衰住院的Kaplan-Meier无事件率分别为87.9%和78.5%。
  • 1年时92%患者NYHA心功能I或II级,6分钟步行距离增加94米。

核心结论

  • PASCAL系统并发症低、生存率高,1年时三尖瓣反流、功能状态和生活质量显著且持续改善。

研究设计与样本

  • 平均年龄77.4岁,女性占55.4%,97.0%为重度至极重度三尖瓣反流。
  • 超声心动图结果由独立核心实验室评估,主要不良事件由临床事件委员会裁定。

主要发现

  • 30天时心血管死亡率为3.1%,卒中率为1.5%,无器械相关再干预报告。
  • 30天至1年间,新增心血管死亡3例(4.8%)、卒中2例(3.2%)、非计划或急诊再干预1例(1.6%)。
  • 1年时三尖瓣反流严重程度显著降低(P < 0.001),36例中31例(86.0%)达到中度或以下反流,100%患者至少降低1个反流等级。
  • 1年全因死亡和心衰住院的Kaplan-Meier无事件率分别为87.9%和78.5%。
  • NYHA心功能分级显著改善(P < 0.001),92%为I或II级;6分钟步行距离增加94米(P = 0.014);KCCQ总分改善18分(P < 0.001)。

临床怎么用

  • 对于重度及以上三尖瓣反流且药物治疗后仍有症状的患者,PASCAL经导管修复系统可作为降低外科手术风险的介入选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical management of isolated tricuspid regurgitation (TR) is associated with high morbidity and mortality, thereby creating a significant need for a lower-risk transcatheter solution. OBJECTIVES: The single-arm, multicenter, prospective CLASP TR (Edwards PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation [CLASP TR] Early Feasibility Study) evaluated 1-year outcomes of the PASCAL transcatheter valve repair system (Edwards Lifesciences) to treat TR. METHODS: Study inclusion required a previous diagnosis of severe or greater TR and persistent symptoms despite medical treatment. An independent core laboratory evaluated echocardiographic results, and a clinical events committee adjudicated major adverse events. The study evaluated primary safety and performance outcomes, with echocardiographic, clinical, and functional endpoints. Study investigators report 1-year all-cause mortality and heart failure hospitalization rates. RESULTS: Sixty-five patients were enrolled: mean age of 77.4 years; 55.4% female; and 97.0% with severe to torrential TR. At 30 days, cardiovascular mortality was 3.1%, the stroke rate was 1.5%, and no device-related reinterventions were reported. Between 30 days and 1 year, there were an additional 3 cardiovascular deaths (4.8%), 2 strokes (3.2%), and 1 unplanned or emergency reintervention (1.6%). One-year postprocedure, TR severity significantly reduced (P < 0.001), with 31 of 36 (86.0%) patients achieving moderate or less TR; 100% had at least 1 TR grade reduction. Freedom from all-cause mortality and heart failure hospitalization by Kaplan-Meier analyses were 87.9% and 78.5%, respectively. Their New York Heart Association functional class significantly improved (P < 0.001) with 92% in class I or II, 6-minute walk distance increased by 94 m (P = 0.014), and overall Kansas City Cardiomyopathy Questionnaire scores improved by 18 points (P < 0.001). CONCLUSIONS: The PASCAL system demonstrated low complication and high survival rates, with significant and sustained improvements in TR, functional status, and quality of life at 1 year. (Edwards PASCAL TrAnScatheter Valve RePair System in Tricuspid Regurgitation [CLASP TR] Early Feasibility Study [CLASP TR EFS]; NCT03745313).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kodali SK, Hahn RT, Davidson CJ, et al. 1-Year Outcomes of Transcatheter Tricuspid Valve Repair. J Am Coll Cardiol. 2023. PMID: 37137586. doi:10.1016/j.jacc.2023.02.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。